PARP inhibitors in ovarian and other cancers.
Newcastle University, Newcastle upon Tyne, United Kingdom.
Ruth
R
Plummer
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D015415:Biomarkers; D000067856:Poly(ADP-ribose) Polymerase Inhibitors